Fairly priced — no edge either way.
Close to fair value. Not a bargain, not a rip-off. Come back if the price moves.
Price against fair value
Free cash flow — 5-year history ($B)
What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.
The read — lights & verdict
- Roughly fairFair value ~$132 sits close to the $129 price — no real margin of safety either way.
- Price is in line with its recordPriced for ~5%/yr, roughly what it has delivered (4.3%/yr).
- Revenue still growingUp 2.4% last year — demand isn't the problem.
- Cash flow compoundingFree cash flow up ~4.3%/yr — the engine is growing.
- Manageable net debtNet debt of $14B — about 1.5× annual free cash flow. Normal for a mature company.
How this was built. Every figure is computed from Gilead Sciences, Inc.'s SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $129.31 taken 2026-07-24 (founder-supplied CSV, July 2026) — it is not live and does not move during the day.